Revolution Medicines, Inc.
RVMD
Rang in Aktien
#580
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Aktienkurs
$194.91
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$41.78B
Veränderung (1 Tag)
-0.83%
Veränderung (1 Jahr)
267.89%
Land
US
Handel Revolution Medicines, Inc. (RVMD)
Kategorie
Healthcare
Kursverlauf für Revolution Medicines, Inc. (RVMD)
Höchster Schlusskurs: $194.37 am 2026-10-01
Niedrigster Schlusskurs: $30.68 am 2020-02-01
Niedrigster Schlusskurs: $30.68 am 2020-02-01
Kursverlauf der Aktie von Revolution Medicines, Inc. von 2020 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 72.78% |
| 2025 | 72.22% |
| 2024 | 75.37% |
| 2023 | 10.12% |
| 2022 | -8.93% |
| 2021 | -38.16% |
| 2020 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
